Yufen Lin1, Donald E Bailey, Sharron L Docherty, Laura S Porter, Bruce A Cooper, Steven M Paul, Marilyn J Hammer, Yvette P Conley, Jon D Levine, Christine Miaskowski. 1. Author affiliations: Schools of Nursing (Ms Lin and Drs Bailey and Docherty) and Medicine (Dr Porter), Duke University, Durham, North Carolina; School of Nursing, University of California, San Francisco (Drs Cooper, Paul, and Miaskowski); Dana Farber Cancer Institute, Boston, Massachusetts (Dr Hammer); School of Nursing, University of Pittsburgh, PA (Dr Conley); School of Medicine, University of California, San Francisco (Drs Miaskowski and Levine).
Abstract
BACKGROUND: Patients with gastrointestinal cancers experience moderate to high levels of sleep disturbance during chemotherapy that decreases their functional status and quality of life (QOL). OBJECTIVE: The objectives of this study were to identify subgroups of patients with gastrointestinal cancers with distinct sleep disturbance profiles and evaluate for differences among these subgroups in demographic, clinical, and sleep characteristics, as well as co-occurring symptoms and QOL outcomes. METHODS: Patients (n = 405) completed questionnaires 6 times over 2 cycles of chemotherapy. Latent profile analysis was used to identify subgroups of patients with distinct sleep disturbance profiles. RESULTS: Three distinct sleep disturbance profiles (ie, low, high, very high) were identified. Compared with the low class, patients in the other 2 classes were significantly younger and less likely to be married and to exercise on a regular basis and received a higher number of previous treatments. Compared with the low class, patients in the other 2 classes reported higher levels of anxiety, depressive symptoms, morning and evening fatigue, and pain and lower levels of attentional function and QOL scores at enrollment. CONCLUSIONS: This study is the first to use latent profile analysis to identify subgroups of patients with gastrointestinal cancers with distinct sleep disturbance profiles. Findings provide new insights on the associations between sleep disturbance and multiple co-occurring symptoms in these patients. IMPLICATIONS FOR PRACTICE: Clinicians can identify patients who are at the highest risk for sleep disturbance and recommend a variety of sleep hygiene interventions (eg, establishment of a bedtime routine), as well as initiate interventions for other co-occurring symptoms.
BACKGROUND: Patients with gastrointestinal cancers experience moderate to high levels of sleep disturbance during chemotherapy that decreases their functional status and quality of life (QOL). OBJECTIVE: The objectives of this study were to identify subgroups of patients with gastrointestinal cancers with distinct sleep disturbance profiles and evaluate for differences among these subgroups in demographic, clinical, and sleep characteristics, as well as co-occurring symptoms and QOL outcomes. METHODS: Patients (n = 405) completed questionnaires 6 times over 2 cycles of chemotherapy. Latent profile analysis was used to identify subgroups of patients with distinct sleep disturbance profiles. RESULTS: Three distinct sleep disturbance profiles (ie, low, high, very high) were identified. Compared with the low class, patients in the other 2 classes were significantly younger and less likely to be married and to exercise on a regular basis and received a higher number of previous treatments. Compared with the low class, patients in the other 2 classes reported higher levels of anxiety, depressive symptoms, morning and evening fatigue, and pain and lower levels of attentional function and QOL scores at enrollment. CONCLUSIONS: This study is the first to use latent profile analysis to identify subgroups of patients with gastrointestinal cancers with distinct sleep disturbance profiles. Findings provide new insights on the associations between sleep disturbance and multiple co-occurring symptoms in these patients. IMPLICATIONS FOR PRACTICE: Clinicians can identify patients who are at the highest risk for sleep disturbance and recommend a variety of sleep hygiene interventions (eg, establishment of a bedtime routine), as well as initiate interventions for other co-occurring symptoms.
Authors: Ilufredo Y Tantoy; Bruce A Cooper; Anand Dhruva; Janine Cataldo; Steven M Paul; Yvette P Conley; Marilyn Hammer; Kord M Kober; Jon D Levine; Christine Miaskowski Journal: Qual Life Res Date: 2018-04-21 Impact factor: 4.147
Authors: Christina Van Onselen; Steven M Paul; Kathryn Lee; Laura Dunn; Bradley E Aouizerat; Claudia West; Marylin Dodd; Bruce Cooper; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2012-08-24 Impact factor: 3.612
Authors: Laura Q Rogers; Kerry S Courneya; K Thomas Robbins; Krishna Rao; James Malone; Alison Seiz; Sheryl Reminger; Stephen J Markwell; Vishal Burra Journal: Head Neck Date: 2008-10 Impact factor: 3.147
Authors: Yufen Lin; Deborah W Bruner; Sudeshna Paul; Andrew H Miller; Nabil F Saba; Kristin A Higgins; Dong M Shin; Wenhui Zhang; Christine Miaskowski; Canhua Xiao Journal: Cancer Date: 2022-08-15 Impact factor: 6.921